Global and extended coagulation monitoring during extracorporeal lung assist with heparin-coated systems in ARDS patients.
Heparin-coated systems for extracorporeal lung-assist (ECLA) were developed to reduce hemorrhagic risk by lowering the systemic heparinization, monitored by global tests, e.g. activated coagulation time (ACT) and activated partial thromboplastin time (APTT). Since this strategy gives no insight into procoagulant states, five ARDS patients receiving ECLA with heparin-coated systems were investivated for changes in coagulation using both global and extended tests. During ECLA onset the APTT and ACT were within or near normal ranges, platelets decreased 76.5% within 48 h, fibrinogen decreased 28.7%, thrombin-antithrombin-III complexes were elevated before ECLA (53 micrograms/L), but demonstrated an additional peak (238 micrograms/L), plasminogen-activator-inhibitor-1 increased 12-fold, and the C1-inhibitor dropped 14.1%. In conclusion, after the onset of ECLA from a previous prethrombotic state, the precoagulant, anticoagulant, fibrinolytic and complement systems were activated in a similar way to that reported for non-heparinized systems with high-dose heparin. This was however only monitored by an extended test panel which was unable to predict thromboembolic events during ECLA.
Gerlach
M
M
Clinic for Anesthesiology and Critical Care Medicine, Virchow-Klinikum, Humboldt University, Berlin, Germany.
Föhre
B
B
Keh
D
D
Riess
H
H
Falke
K J
KJ
Gerlach
H
H
D000328:Adult; D000704:Analysis of Variance; D000925:Anticoagulants / Q000494:pharmacology*; D000990:Antithrombin III / Q000187:drug effects; D001777:Blood Coagulation / Q000187:drug effects; D005112:Extracorporeal Circulation / Q000009:adverse effects; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D008168:Lung / Q000098:blood supply*; D008297:Male; D008567:Membranes, Artificial; D008991:Monitoring, Physiologic; D010314:Partial Thromboplastin Time; D010447:Peptide Hydrolases / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D012128:Respiratory Distress Syndrome / Q000503:physiopathology / Q000628:therapy*; D013923:Thromboembolism / Q000401:mortality / Q000517:prevention & control
D000925:Anticoagulants; D008567:Membranes, Artificial; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D005340:Fibrinogen; D006493:Heparin; D010447:Peptide Hydrolases